These first-generation radiotracers initially developed for AD have generated considerable interest for their potential to quantify the topological distribution of tau, which can be valuable in monitoring disease progression and improving clinical diagnosis of PSP and CBS. This evidence concerns the gene MAPT and Alzheimer disease.